Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in Pediatrics, 8, 2020
- Schlagwort
-
-
- Ereignis
-
Veröffentlichung
- (wo)
-
Greifswald
- (wer)
-
Universität Greifswald
- (wann)
-
2020
- Urheber
-
Cicek, Filiz
Troschke-Meurer, Sascha
Ceylan, Kiraz
Jahns, Luciana J.
Zumpe, Maxi
Siebert, Nikolai
Ehlert, Karoline
Lode, Holger N.
- DOI
-
10.3389/fped.2020.582820
- URN
-
urn:nbn:de:gbv:9-opus-42271
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cicek, Filiz
- Troschke-Meurer, Sascha
- Ceylan, Kiraz
- Jahns, Luciana J.
- Zumpe, Maxi
- Siebert, Nikolai
- Ehlert, Karoline
- Lode, Holger N.
- Universität Greifswald
Entstanden
- 2020
Ähnliche Objekte (12)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Neuroblastoma : with 48 tables
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Impact of FCGR Polymorphisms and KIR/HLA Mismatch on outcome following Immunotherapy of Neuroblastoma patients with ch14.18/CHO combination with IL-2
Functional validation of novel target structures for treatment of high-risk neuroblastoma
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Localized immunotherapy with self-amplifying RNA immunotherapy in murine solid tumor models
Renal denervation in high-risk patients with hypertension
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : : Melanoma brain metastases prognostic score
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Neuroblastoma : with 48 tables
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Impact of FCGR Polymorphisms and KIR/HLA Mismatch on outcome following Immunotherapy of Neuroblastoma patients with ch14.18/CHO combination with IL-2
Functional validation of novel target structures for treatment of high-risk neuroblastoma
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Localized immunotherapy with self-amplifying RNA immunotherapy in murine solid tumor models
Renal denervation in high-risk patients with hypertension
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : : Melanoma brain metastases prognostic score
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Neuroblastoma : with 48 tables
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
Impact of FCGR Polymorphisms and KIR/HLA Mismatch on outcome following Immunotherapy of Neuroblastoma patients with ch14.18/CHO combination with IL-2
Functional validation of novel target structures for treatment of high-risk neuroblastoma
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Localized immunotherapy with self-amplifying RNA immunotherapy in murine solid tumor models
Renal denervation in high-risk patients with hypertension